{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:49:32Z","timestamp":1764784172757,"version":"build-2065373602"},"reference-count":75,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.sapharm.2018.12.007","type":"journal-article","created":{"date-parts":[[2018,12,24]],"date-time":"2018-12-24T12:08:07Z","timestamp":1545653287000},"page":"1317-1325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Benzodiazepine use risk: Understanding patient specific risk perceptions and medication beliefs"],"prefix":"10.1016","volume":"15","author":[{"given":"Fatema-Tun-Naher","family":"Sake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5191-5233","authenticated-orcid":false,"given":"Keith","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delwyn J.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bandana","family":"Saini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.sapharm.2018.12.007_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/13651500903447810","article-title":"Usage of benzodiazepines: a review","volume":"14","author":"Donoghue","year":"2010","journal-title":"Int J Psychiatr Clin Pract"},{"key":"10.1016\/j.sapharm.2018.12.007_bib2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2296-12-28","article-title":"Gaining insight into benzodiazepine prescribing in General Practice in France: a data-based study","volume":"12","author":"Rosman","year":"2011","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.sapharm.2018.12.007_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","article-title":"Benzodiazepine use in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.sapharm.2018.12.007_bib4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1192\/apt.bp.110.008631","article-title":"Benzodiazepines for anxiety disorders: maximising the benefits and minimising the risks","volume":"18","author":"Starcevic","year":"2012","journal-title":"Adv Psychiatr Treat"},{"key":"10.1016\/j.sapharm.2018.12.007_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1472-8206.2006.00400.x","article-title":"Benzodiazepines prescription in Dakar: a study about prescribing habits and knowledge in general practitioners, neurologists and psychiatrists","volume":"20","author":"Di\u00e8ye","year":"2006","journal-title":"Fund Clin Pharmacol"},{"key":"10.1016\/j.sapharm.2018.12.007_bib6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s13311-012-0148-3","article-title":"Insomnia pharmacotherapy","volume":"9","author":"Roehrs","year":"2012","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.sapharm.2018.12.007_bib7","first-page":"501","article-title":"Benzodiazepines revisited","volume":"5","author":"Mehdi","year":"2012","journal-title":"Br J Med Pract"},{"key":"10.1016\/j.sapharm.2018.12.007_bib8","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/archinternmed.2009.357","article-title":"Meta-analysis of the impact of 9 medication classes on falls in elderly persons","volume":"169","author":"Woolcott","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.sapharm.2018.12.007_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5414\/CP202134","article-title":"Association of fracture risk with benzodiazepine among adults in South Korea","volume":"53","author":"Hwang","year":"2015","journal-title":"Int J Clin Pharm Ther"},{"key":"10.1016\/j.sapharm.2018.12.007_bib10","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1046\/j.1532-5415.2002.50254.x","article-title":"Is the use of benzodiazepines associated with incident disability?","volume":"50","author":"Gray","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.sapharm.2018.12.007_bib11","first-page":"639","article-title":"A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs","volume":"29","author":"Tannenbaum","year":"2012","journal-title":"Drugs Aging"},{"key":"10.1016\/j.sapharm.2018.12.007_bib12","first-page":"24","article-title":"Benzodiazepines: benefits versus risks","volume":"1","author":"West","year":"2007","journal-title":"Journal of the Malta College of Pharmacy Practice"},{"key":"10.1016\/j.sapharm.2018.12.007_bib13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2125.2012.04418.x","article-title":"Benzodiazepine harm: how can it be reduced?","volume":"77","author":"Lader","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.sapharm.2018.12.007_bib14","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/JGP.0b013e3181a65210","article-title":"The association between dementia and long-term use of benzodiazepine in the elderly: nested case\u2013control study using claims data","volume":"17","author":"Wu","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"year":"2015","series-title":"Prescribing Drugs of Dependence in General Practice, Part B. Melbourne","author":"The Royal Australian College of General Practitioners","key":"10.1016\/j.sapharm.2018.12.007_bib15"},{"key":"10.1016\/j.sapharm.2018.12.007_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1176\/ajp.148.2.151","article-title":"The APA task force report on benzodiazepine depedence, toxicity, and abuse","volume":"148","author":"Salzman","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.sapharm.2018.12.007_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/0004867412466595","article-title":"Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011","volume":"47","author":"Stephenson","year":"2013","journal-title":"Aust N Z J Psychiatr"},{"key":"10.1016\/j.sapharm.2018.12.007_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1753-6405.2010.00573.x","article-title":"Medications used in overdose and how they are acquired\u2013an investigation of cases attending an inner Melbourne emergency department","volume":"34","author":"Buykx","year":"2010","journal-title":"Aust N Z J Public Health"},{"key":"10.1016\/j.sapharm.2018.12.007_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/imj.12315","article-title":"Twenty\u2010year trends in benzodiazepine dispensing in the Australian population","volume":"44","author":"Islam","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.sapharm.2018.12.007_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1447-0594.2008.00462.x","article-title":"Reducing psychotropic medications in elderly rehabilitation inpatients with a fall\u2010related admission: how often is it happening?","volume":"8","author":"Clements","year":"2008","journal-title":"Geriatr Gerontol Int"},{"year":"2016","series-title":"Next-morning Effects of Hypnotic Drugs on Attention, Psychomotor Performance, and Memory Functioning: Implications for Traffic Safety","author":"Verster","key":"10.1016\/j.sapharm.2018.12.007_bib21"},{"key":"10.1016\/j.sapharm.2018.12.007_bib22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.smrv.2004.02.001","article-title":"Residual effects of sleep medication on driving ability","volume":"8","author":"Verster","year":"2004","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sapharm.2018.12.007_bib23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1742-6723.2007.00958.x","article-title":"Drug use in motor vehicle drivers presenting to an Australian, adult major trauma centre","volume":"19","author":"Ch\u2019ng","year":"2007","journal-title":"Emerg Med Australasia (EMA)"},{"key":"10.1016\/j.sapharm.2018.12.007_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/15389588.2012.729278","article-title":"Consumer perceptions of medication warnings about driving: a comparison of French and Australian labels","volume":"14","author":"Smyth","year":"2013","journal-title":"Traffic Inj Prev"},{"key":"10.1016\/j.sapharm.2018.12.007_bib25","doi-asserted-by":"crossref","first-page":"A276","DOI":"10.1289\/ehp.122-A276","article-title":"Risk perception: it's personal","volume":"122","author":"Brown","year":"2014","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.sapharm.2018.12.007_bib26","first-page":"65","article-title":"Facts and fears: understanding perceived risk (1979)","volume":"3","author":"Slovic","year":"2005","journal-title":"Pol Pract Health Saf"},{"key":"10.1016\/j.sapharm.2018.12.007_bib27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.drugalcdep.2015.02.009","article-title":"Perceived risk of regular cannabis use in the United States from 2002 to 2012: differences by sex, age, and race\/ethnicity","volume":"149","author":"Pacek","year":"2015","journal-title":"Drug Alcohol Depend"},{"year":"2007","series-title":"Drugs and Driving in Australia: A Survey of Community Attitudes, Experience and Understanding. Melbourne","author":"Mallick","key":"10.1016\/j.sapharm.2018.12.007_bib28"},{"key":"10.1016\/j.sapharm.2018.12.007_bib29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40264-017-0542-1","article-title":"People's understanding of verbal risk descriptors in patient information leaflets: a cross-sectional national survey of 18- to 65-year-olds in england","volume":"40","author":"Webster","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.sapharm.2018.12.007_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-2125.2006.02739_1.x","article-title":"Risk perception in drug therapy","volume":"62","author":"Aronson","year":"2006","journal-title":"Br J Clin Pharmacol"},{"year":"2003","series-title":"Workplace Threats to Health and Job Turnover Among Women Workers","author":"Gucer","key":"10.1016\/j.sapharm.2018.12.007_bib31"},{"key":"10.1016\/j.sapharm.2018.12.007_bib32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(88)92535-4","article-title":"The Nottingham study of neurotic disorder: comparison of drug and psychological treatments","volume":"332","author":"Tyrer","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.sapharm.2018.12.007_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2296-13-40","article-title":"Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review","volume":"13","author":"Mitchell","year":"2012","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.sapharm.2018.12.007_bib34","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/jama.281.11.991","article-title":"Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial","volume":"281","author":"Morin","year":"1999","journal-title":"Jama"},{"key":"10.1016\/j.sapharm.2018.12.007_bib35","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000092892","article-title":"Comparison of sleep condition and sleep-related psychological activity after cognitive-behavior and pharmacological therapy for chronic insomnia","volume":"75","author":"Wu","year":"2006","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.sapharm.2018.12.007_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/0023210-200923010-00002","article-title":"Withdrawing benzodiazepines in primary care","volume":"23","author":"Lader","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sapharm.2018.12.007_bib37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2165\/00019053-200624070-00007","article-title":"Tapering off benzodiazepines in long-term users","volume":"24","author":"Voshaar","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.sapharm.2018.12.007_bib38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.5694\/mja14.00146","article-title":"First do no harm: a real need to deprescribe in older patients","volume":"201","author":"Scott","year":"2014","journal-title":"Med J Aust"},{"key":"10.1016\/j.sapharm.2018.12.007_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.copsyc.2015.03.012","article-title":"Risk perceptions and health behavior","volume":"5","author":"Ferrer","year":"2015","journal-title":"Current opinion in psychology"},{"key":"10.1016\/j.sapharm.2018.12.007_bib40","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.addbeh.2011.03.003","article-title":"Risk perception and motivation to quit smoking: a partial test of the Health Action Process Approach","volume":"36","author":"Williams","year":"2011","journal-title":"Addict Behav"},{"key":"10.1016\/j.sapharm.2018.12.007_bib41","doi-asserted-by":"crossref","first-page":"e015959","DOI":"10.1136\/bmjopen-2017-015959","article-title":"A realist evaluation of patients' decisions to deprescribe in the EMPOWER trial","volume":"7","author":"Martin","year":"2017","journal-title":"BMJ open"},{"key":"10.1016\/j.sapharm.2018.12.007_bib42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/15389580590903168","article-title":"Drug and drink driving by university students: an exploration of the influence of attitudes","volume":"6","author":"Davey","year":"2005","journal-title":"Traffic Inj Prev"},{"year":"2013","series-title":"Designing Clinical Research : An Epidemiologic Approach","author":"Hulley","key":"10.1016\/j.sapharm.2018.12.007_bib43"},{"key":"10.1016\/j.sapharm.2018.12.007_bib44","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jpain.2015.05.002","article-title":"Estimates of pain prevalence and severity in adults: United States, 2012","volume":"16","author":"Nahin","year":"2015","journal-title":"J Pain"},{"key":"10.1016\/j.sapharm.2018.12.007_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10865-013-9523-8","article-title":"Minority stress and physical health among sexual minority individuals","volume":"38","author":"Frost","year":"2015","journal-title":"J Behav Med"},{"year":"2010","series-title":"Mapping Drug Driving, Drug Use and Risk Perceptions of On-road Drivers, Entertainment-venue Attendees and Newly-licensed Drivers in the Australian Capital Territory","author":"Martinez","key":"10.1016\/j.sapharm.2018.12.007_bib46"},{"key":"10.1016\/j.sapharm.2018.12.007_bib47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/009286150704100110","article-title":"Risk perception of prescription drugs: results of a national survey","volume":"41","author":"Slovic","year":"2007","journal-title":"Drug Inf J"},{"year":"1993","series-title":"Health-risk Perception in Canada","author":"Slovic","key":"10.1016\/j.sapharm.2018.12.007_bib48"},{"key":"10.1016\/j.sapharm.2018.12.007_bib49","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/1471-2458-13-216","article-title":"Drowning deaths in Sweden with emphasis on the presence of alcohol and drugs \u2013 a retrospective study, 1992\u20132009","volume":"13","author":"Ahlm","year":"2013","journal-title":"BMC Public Health"},{"key":"10.1016\/j.sapharm.2018.12.007_bib50","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.sapharm.2017.04.042","article-title":"Medications affecting alertness: beliefs and perceptions of consumers","volume":"13","author":"Liew","year":"2017","journal-title":"Res Soc Adm Pharm"},{"key":"10.1016\/j.sapharm.2018.12.007_bib51","series-title":"Fear as Motivator, Fear as Inhibitor-Chapter 16:Using the Extended Parallel Process Model to Explain Fear Appeal Successes and Failures","first-page":"423","author":"Witte","year":"1998"},{"key":"10.1016\/j.sapharm.2018.12.007_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08870449908407311","article-title":"The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication","volume":"14","author":"Horne","year":"1999","journal-title":"Psychol Health"},{"key":"10.1016\/j.sapharm.2018.12.007_bib53","first-page":"1","article-title":"Cronbach's alpha: a tool for assessing the reliability of scales","volume":"37","author":"Santos","year":"1999","journal-title":"J Ext"},{"key":"10.1016\/j.sapharm.2018.12.007_bib54","first-page":"785","article-title":"Time trends in the family physician management of insomnia: the Australian experience (2000\u20132015)","volume":"13","author":"Miller","year":"2017","journal-title":"J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med"},{"key":"10.1016\/j.sapharm.2018.12.007_bib55","first-page":"101","article-title":"Hypnotic action and residual effects of a single bedtime dose of temazepam","volume":"34","author":"Borbely","year":"1984","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.sapharm.2018.12.007_bib56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/1381612023396654","article-title":"Cognitive and sedative effects of benzodiazepine use","volume":"8","author":"Buffett-Jerrott","year":"2002","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.sapharm.2018.12.007_bib57","first-page":"1263","article-title":"Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance","volume":"74","author":"Paul","year":"2003","journal-title":"Aviat Space Environ Med"},{"key":"10.1016\/j.sapharm.2018.12.007_bib58","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1046\/j.1532-5415.2003.51502.x","article-title":"Benzodiazepine use and physical performance in community\u2010dwelling older women","volume":"51","author":"Gray","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.sapharm.2018.12.007_bib59","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/0272-4332.205065","article-title":"Protection motivation and risk communication","volume":"20","author":"Neuwirth","year":"2000","journal-title":"Risk Anal"},{"key":"10.1016\/j.sapharm.2018.12.007_bib60","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/03637759209376276","article-title":"Putting the fear back into fear appeals: the extended parallel process model","volume":"59","author":"Witte","year":"1992","journal-title":"Commun Monogr"},{"key":"10.1016\/j.sapharm.2018.12.007_bib61","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/0897190010397720","article-title":"Counseling techniques to address male communication characteristics: an application of the extended parallel process model","volume":"24","author":"Puja","year":"2011","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.sapharm.2018.12.007_bib62","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1177\/0733464814544214","article-title":"Health risk perceptions and exercise in older adulthood: an application of protection motivation theory","volume":"35","author":"Ruthig","year":"2016","journal-title":"J Appl Gerontol"},{"key":"10.1016\/j.sapharm.2018.12.007_bib63","first-page":"291","article-title":"Application of protection motivation theory (PMT) and health action process approach (HAPA) in promoting women's adaptive engagement towards breast self examination","volume":"5","author":"Daniel","year":"2014","journal-title":"Acad Res Int"},{"key":"10.1016\/j.sapharm.2018.12.007_bib64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1360-0443.2004.00564.x","article-title":"The efficacy of single\u2010session motivational interviewing in reducing drug consumption and perceptions of drug\u2010related risk and harm among young people: results from a multi\u2010site cluster randomized trial","volume":"99","author":"McCambridge","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.sapharm.2018.12.007_bib65","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/01445442-200305000-00013","article-title":"Motivational interviewing: preparing people for change","volume":"25","author":"Miller","year":"2003","journal-title":"J Healthc Qual"},{"key":"10.1016\/j.sapharm.2018.12.007_bib66","series-title":"Motivational Interviewing: Preparing People for Change","first-page":"58","author":"Miller","year":"2002"},{"key":"10.1016\/j.sapharm.2018.12.007_bib67","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/pon.3899","article-title":"Effectiveness of the extended parallel process model in promoting colorectal cancer screening","volume":"24","author":"Birmingham","year":"2015","journal-title":"Psycho Oncol"},{"year":"2002","series-title":"Protection Motivation Theory and Exercise Behaviour Change for the Prevention of Heart Disease in a High-risk, Australian Representative Community Sample of Adults","author":"Plotnikoff","key":"10.1016\/j.sapharm.2018.12.007_bib68"},{"key":"10.1016\/j.sapharm.2018.12.007_bib69","unstructured":"Australian Institute of Health and Welfare. Australia's health 20122012:628.."},{"key":"10.1016\/j.sapharm.2018.12.007_bib70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/2231-4040.137383","article-title":"Role of pharmacists in retailing of drugs","volume":"5","author":"Sinha","year":"2014","journal-title":"J Adv Pharm Technol Research"},{"key":"10.1016\/j.sapharm.2018.12.007_bib71","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/jamainternmed.2014.949","article-title":"Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial","volume":"174","author":"Tannenbaum","year":"2014","journal-title":"JAMA Intern Med"},{"year":"2011","series-title":"A 12-month Follow-up Study of \"RedUSe\": A Trial Aimed at Reducing Antipsychotic and Benzodiazepine Use in Nursing Homes","author":"Westbury","key":"10.1016\/j.sapharm.2018.12.007_bib72"},{"key":"10.1016\/j.sapharm.2018.12.007_bib73","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2710.2009.01079.x","article-title":"Psycholeptic use in aged care homes in Tasmania, Australia","volume":"35","author":"Westbury","year":"2010","journal-title":"J Clin Pharm Therapeut"},{"key":"10.1016\/j.sapharm.2018.12.007_bib74","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.sapharm.2016.12.010","article-title":"Pharmacists' perceptions and communication of risk for alertness impairing medications","volume":"14","author":"Jomaa","year":"2018","journal-title":"Res Soc Adm Pharm"},{"year":"2012","series-title":"Medicines and Driving: Evaluation of Training and Software Support for Patient Counselling by Pharmacists","author":"Legrand","key":"10.1016\/j.sapharm.2018.12.007_bib75"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155174111830576X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155174111830576X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:17:09Z","timestamp":1761556629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155174111830576X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":75,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S155174111830576X"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2018.12.007","relation":{},"ISSN":["1551-7411"],"issn-type":[{"type":"print","value":"1551-7411"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benzodiazepine use risk: Understanding patient specific risk perceptions and medication beliefs","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2018.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}